vTv Therapeutics (VTVT) Revenue & Revenue Breakdown
vTv Therapeutics Revenue Highlights
00
vTv Therapeutics Revenue by Period
vTv Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | -100.00% |
2022-12-31 | $2.02M | -49.61% |
2021-12-31 | $4.00M | -37.56% |
2020-12-31 | $6.41M | 132.05% |
2019-12-31 | $2.76M | -77.77% |
2018-12-31 | $12.43M | 4172.85% |
2017-12-31 | $291.00K | -54.10% |
2016-12-31 | $634.00K | 22.16% |
2015-12-31 | $519.00K | -66.49% |
2014-12-31 | $1.55M | 58.71% |
2013-12-31 | $976.00K | - |
vTv Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | -100.00% |
2024-03-31 | $1.00M | -11211.11% |
2023-12-31 | $-9.00K | 100.00% |
2023-09-30 | - | -100.00% |
2023-06-30 | $9.00K | 100.00% |
2023-03-31 | - | -100.00% |
2022-12-31 | $9.00K | 100.00% |
2022-09-30 | - | -100.00% |
2022-06-30 | $9.00K | -99.55% |
2022-03-31 | $2.00M | 22122.22% |
2021-12-31 | $9.00K | -99.70% |
2021-09-30 | $3.00M | 33233.33% |
2021-06-30 | $9.00K | -99.09% |
2021-03-31 | $987.00K | -84.58% |
2020-12-31 | $6.40M | 91314.29% |
2020-09-30 | $7.00K | 100.00% |
2020-06-30 | - | -100.00% |
2020-03-31 | $8.00K | 14.29% |
2019-12-31 | $7.00K | -12.50% |
2019-09-30 | $8.00K | -99.56% |
2019-06-30 | $1.83M | 98.48% |
2019-03-31 | $921.00K | -79.63% |
2018-12-31 | $4.52M | 33.99% |
2018-09-30 | $3.38M | 36.47% |
2018-06-30 | $2.47M | 19.82% |
2018-03-31 | $2.06M | 785.84% |
2017-12-31 | $233.00K | 1453.33% |
2017-09-30 | $15.00K | 15.38% |
2017-06-30 | $13.00K | -56.67% |
2017-03-31 | $30.00K | -21.05% |
2016-12-31 | $38.00K | - |
2016-09-30 | $38.00K | -79.12% |
2016-06-30 | $182.00K | -51.60% |
2016-03-31 | $376.00K | 66.37% |
2015-12-31 | $226.00K | 69.92% |
2015-09-30 | $133.00K | 20.91% |
2015-06-30 | $110.00K | 120.00% |
2015-03-31 | $50.00K | -94.65% |
2014-12-31 | $934.00K | 133.50% |
2014-09-30 | $400.00K | 99.00% |
2014-06-30 | $201.00K | 1335.71% |
2014-03-31 | $14.00K | - |
vTv Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
INM | InMed Pharmaceuticals | $6.56B | $2.04B |
SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
KRON | Kronos Bio | $6.29M | $2.37M |
GBIO | Generation Bio | $5.90M | $4.09M |
VRAX | Virax Biolabs Group | $8.56K | $76.50K |
NRBO | NeuroBo Pharmaceuticals | $7.00K | - |
CCCC | C4 Therapeutics | - | - |
CYTO | Altamira Therapeutics | - | $52.73K |
ZURA | Zura Bio | - | - |
ELEV | Elevation Oncology | - | - |
HILS | Tharimmune | - | - |
ERAS | Erasca | - | - |
GOVX | GeoVax Labs | - | $300.68K |
PYXS | Pyxis Oncology | - | - |
PHIO | Phio Pharmaceuticals | - | - |
IMMX | Immix Biopharma | - | - |
ALLR | Allarity Therapeutics | - | - |
EWTX | Edgewise Therapeutics | - | - |
VTVT | vTv Therapeutics | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
QNRX | Quoin Pharmaceuticals | - | - |